• Alector to Participate at the Cowen 42nd Annual Health Care Conference

    ソース: Nasdaq GlobeNewswire / 01 3 2022 16:05:02   America/New_York

    SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the Cowen Annual Health Care Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

    A live webcast of the panel will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.

    About Alector
    Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com

    Contacts:

    1AB (media)
    Dan Budwick
    973-271-6085
    dan@1abmedia.com

    Argot Partners (investors)
    Eric Kasper/Carrie McKim
    Argot Partners
    212.600.1902
    alector@argotpartners.com


    Primary Logo

シェアする